Causes, Characteristics, and Consequences of Metabolically Unhealthy Normal Weight in Humans

Cell Metabolism

Volumn 26, Issue 2, 2017, Pages 292-300

  Stefan, Norbert ^a,b,c   Schick, Fritz ^a,b,c   Häring, Hans Ulrich ^a,b,c  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c GERMAN CENTER FOR DIABETES RESEARCH DZD   (Germany)

Author keywords

cardiometabolic diseases; insulin resistance; insulin secretion; leg fat mass; lipodystrophy like phenotype; metabolic syndrome; metabolically healthy obesity; metabolically unhealthy normal weight; nonalcoholic fatty liver disease; visceral obesity

Indexed keywords

ALL CAUSE MORTALITY; BODY MASS; BODY WEIGHT; CARDIOMETABOLIC RISK; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; HUMAN; LIPODYSTROPHY; METABOLIC DISORDER; OBESITY; PRIORITY JOURNAL; REVIEW; FEMALE; HEART DISEASE; MALE; METABOLISM; PATHOLOGY; RISK FACTOR;

ADIPOSITY; BODY MASS INDEX; FEMALE; HEART DISEASES; HUMANS; MALE; METABOLIC DISEASES; RISK FACTORS;

EID: 85030675839     PISSN: 15504131     EISSN: 19327420     Source Type: Journal    
DOI: 10.1016/j.cmet.2017.07.008     Document Type: Review

References (82)

1. Ahima, R.S., Lazar, M.A., Physiology. The health risk of obesity–better metrics imperative. Science 341 (2013), 856–858.
2. Aleksandrova, K., Nimptsch, K., Pischon, T., Influence of obesity and related metabolic alterations on colorectal cancer risk. Curr. Nutr. Rep. 2 (2013), 1–9.
3. American Diabetes Association. 5. Prevention or Delay of Type 2 Diabetes. Diabetes Care 40:Suppl 1 (2017), S44–S47.
4. Arner, P., Arner, E., Hammarstedt, A., Smith, U., Genetic predisposition for Type 2 diabetes, but not for overweight/obesity, is associated with a restricted adipogenesis. PLoS One, 6, 2011, e18284.
5. Blüher, M., Are metabolically healthy obese individuals really healthy?. Eur. J. Endocrinol. 171 (2014), R209–R219.
6. Cao, H., Gerhold, K., Mayers, J.R., Wiest, M.M., Watkins, S.M., Hotamisligil, G.S., Identification of a lipokine, a lipid hormone linking adipose tissue to systemic metabolism. Cell 134 (2008), 933–944.
7. Carr, A., Workman, C., Carey, D., Rogers, G., Martin, A., Baker, D., Wand, H., Law, M., Samaras, K., Emery, S., Cooper, D.A., Rosey investigators. No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial. Lancet 363 (2004), 429–438.
8. Danforth, E. Jr., Failure of adipocyte differentiation causes type II diabetes mellitus?. Nat. Genet., 26, 2000, 13.
9. DeFronzo, R.A., Tripathy, D., Schwenke, D.C., Banerji, M., Bray, G.A., Buchanan, T.A., Clement, S.C., Henry, R.R., Hodis, H.N., Kitabchi, A.E., et al., ACT NOW Study. Pioglitazone for diabetes prevention in impaired glucose tolerance. N. Engl. J. Med. 364 (2011), 1104–1115.
10. Després, J.P., Lemieux, I., Abdominal obesity and metabolic syndrome. Nature 444 (2006), 881–887.
11. Di Angelantonio, E., Bhupathiraju, ShN., Wormser, D., Gao, P., Kaptoge, S., Berrington de Gonzalez, A., Cairns, B.J., Huxley, R., Jackson, ChL., Joshy, G., et al., Global BMI Mortality Collaboration. Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents. Lancet 388 (2016), 776–786.
12. Drucker, D.J., The Cardiovascular Biology of Glucagon-like Peptide-1. Cell Metab. 24 (2016), 15–30.
13. Dubé J.J., Amati, F., Stefanovic-Racic, M., Toledo, F.G., Sauers, S.E., Goodpaster, B.H., Exercise-induced alterations in intramyocellular lipids and insulin resistance: the athlete's paradox revisited. Am. J. Physiol. Endocrinol. Metab. 294 (2008), E882–E888.
14. Eckel, R.H., Jakicic, J.M., Ard, J.D., de Jesus, J.M., Houston Miller, N., Hubbard, V.S., Lee, I.M., Lichtenstein, A.H., Loria, C.M., Millen, B.E., et al., American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 AHA/ACC guideline on lifestyle management to reduce cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 129:25 Suppl 2 (2014), S76–S99.
15. Eckel, N., Mühlenbruch, K., Meidtner, K., Boeing, H., Stefan, N., Schulze, M.B., Characterization of metabolically unhealthy normal-weight individuals: risk factors and their associations with type 2 diabetes. Metabolism 64 (2015), 862–871.
16. Edgeworth, A., Treacy, M.P., Hurst, T.P., Thiazolidinediones in the treatment of HIV/HAART-associated lipodystrophy syndrome. AIDS Rev. 15 (2013), 171–180.
17. Fabbrini, E., Magkos, F., Mohammed, B.S., Pietka, T., Abumrad, N.A., Patterson, B.W., Okunade, A., Klein, S., Intrahepatic fat, not visceral fat, is linked with metabolic complications of obesity. Proc. Natl. Acad. Sci. USA 106 (2009), 15430–15435.
18. Færch, K., Torekov, S.S., Vistisen, D., Johansen, N.B., Witte, D.R., Jonsson, A., Pedersen, O., Hansen, T., Lauritzen, T., Sandbæk, A., et al. GLP-1 Response to Oral Glucose Is Reduced in Prediabetes, Screen-Detected Type 2 Diabetes, and Obesity and Influenced by Sex: The ADDITION-PRO Study. Diabetes 64 (2015), 2513–2525.
19. Fall, T., Hägg, S., Mägi, R., Ploner, A., Fischer, K., Horikoshi, M., Sarin, A.P., Thorleifsson, G., Ladenvall, C., Kals, M., et al., European Network for Genetic and Genomic Epidemiology (ENGAGE) consortium. The role of adiposity in cardiometabolic traits: a Mendelian randomization analysis. PLoS Med., 10, 2013, e1001474.
20. Flegal, K.M., Kit, B.K., Orpana, H., Graubard, B.I., Association of all-cause mortality with overweight and obesity using standard body mass index categories: a systematic review and meta-analysis. JAMA 309 (2013), 71–82.
21. Fox, C.S., Massaro, J.M., Hoffmann, U., Pou, K.M., Maurovich-Horvat, P., Liu, C.Y., Vasan, R.S., Murabito, J.M., Meigs, J.B., Cupples, L.A., et al. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation 116 (2007), 39–48.
22. Gandotra, S., Le Dour, C., Bottomley, W., Cervera, P., Giral, P., Reznik, Y., Charpentier, G., Auclair, M., Delépine, M., Barroso, I., et al. Perilipin deficiency and autosomal dominant partial lipodystrophy. N. Engl. J. Med. 364 (2011), 740–748.
23. Garg, A., Acquired and inherited lipodystrophies. N. Engl. J. Med. 350 (2004), 1220–1234.
24. Garg, A., Clinical review#: Lipodystrophies: genetic and acquired body fat disorders. J. Clin. Endocrinol. Metab. 96 (2011), 3313–3325.
25. Gavrila, A., Hsu, W., Tsiodras, S., Doweiko, J., Gautam, S., Martin, L., Moses, A.C., Karchmer, A.W., Mantzoros, C.S., Improvement in highly active antiretroviral therapy-induced metabolic syndrome by treatment with pioglitazone but not with fenofibrate: a 2 x 2 factorial, randomized, double-blinded, placebo-controlled trial. Clin. Infect. Dis. 40 (2005), 745–749.
26. Ginsberg, H.N., Insulin resistance and cardiovascular disease. J. Clin. Invest. 106 (2000), 453–458.
27. Goodpaster, B.H., Krishnaswami, S., Harris, T.B., Katsiaras, A., Kritchevsky, S.B., Simonsick, E.M., Nevitt, M., Holvoet, P., Newman, A.B., Obesity, regional body fat distribution, and the metabolic syndrome in older men and women. Arch. Intern. Med. 165 (2005), 777–783.
28. Gujral, U.P., Vittinghoff, E., Mongraw-Chaffin, M., Vaidya, D., Kandula, N.R., Allison, M., Carr, J., Liu, K., Narayan, K.M.V., Kanaya, A.M., Cardiometabolic Abnormalities Among Normal-Weight Persons From Five Racial/Ethnic Groups in the United States: A Cross-sectional Analysis of Two Cohort Studies. Ann. Intern. Med. 166 (2017), 628–636.
29. Hughes, V., The big fat truth. Nature 497 (2013), 428–430.
30. Karelis, A.D., Rabasa-Lhoret, R., Inclusion of C-reactive protein in the identification of metabolically healthy but obese (MHO) individuals. Diabetes Metab. 34 (2008), 183–184.
31. Karelis, A.D., St-Pierre, D.H., Conus, F., Rabasa-Lhoret, R., Poehlman, E.T., Metabolic and body composition factors in subgroups of obesity: what do we know?. J. Clin. Endocrinol. Metab. 89 (2004), 2569–2575.
32. Karpe, F., Pinnick, K.E., Biology of upper-body and lower-body adipose tissue–link to whole-body phenotypes. Nat. Rev. Endocrinol. 11 (2015), 90–100.
33. Kramer, C.K., Zinman, B., Retnakaran, R., Are metabolically healthy overweight and obesity benign conditions?: A systematic review and meta-analysis. Ann. Intern. Med. 159 (2013), 758–769.
34. Kusminski, C.M., Bickel, P.E., Scherer, P.E., Targeting adipose tissue in the treatment of obesity-associated diabetes. Nat. Rev. Drug Discov. 15 (2016), 639–660.
35. Laakso, M., Kuusisto, J., Insulin resistance and hyperglycaemia in cardiovascular disease development. Nat. Rev. Endocrinol. 10 (2014), 293–302.
36. Lillioja, S., Mott, D.M., Spraul, M., Ferraro, R., Foley, J.E., Ravussin, E., Knowler, W.C., Bennett, P.H., Bogardus, C., Insulin resistance and insulin secretory dysfunction as precursors of non-insulin-dependent diabetes mellitus. Prospective studies of Pima Indians. N. Engl. J. Med. 329 (1993), 1988–1992.
37. Lorenz, M.W., Markus, H.S., Bots, M.L., Rosvall, M., Sitzer, M., Prediction of clinical cardiovascular events with carotid intima-media thickness: a systematic review and meta-analysis. Circulation 115 (2007), 459–467.
38. Lotta, L.A., Abbasi, A., Sharp, S.J., Sahlqvist, A.S., Waterworth, D., Brosnan, J.M., Scott, R.A., Langenberg, C., Wareham, N.J., Definitions of Metabolic Health and Risk of Future Type 2 Diabetes in BMI Categories: A Systematic Review and Network Meta-analysis. Diabetes Care 38 (2015), 2177–2187.
39. Lotta, L.A., Gulati, P., Day, F.R., Payne, F., Ongen, H., van de Bunt, M., Gaulton, K.J., Eicher, J.D., Sharp, S.J., Luan, J., et al. EPIC-InterAct Consortium, Cambridge FPLD1 Consortium. Integrative genomic analysis implicates limited peripheral adipose storage capacity in the pathogenesis of human insulin resistance. Nat. Genet. 49 (2017), 17–26.
40. Marinou, K., Hodson, L., Vasan, S.K., Fielding, B.A., Banerjee, R., Brismar, K., Koutsilieris, M., Clark, A., Neville, M.J., Karpe, F., Structural and functional properties of deep abdominal subcutaneous adipose tissue explain its association with insulin resistance and cardiovascular risk in men. Diabetes Care 37 (2014), 821–829.
41. Marso, S.P., Daniels, G.H., Brown-Frandsen, K., Kristensen, P., Mann, J.F., Nauck, M.A., Nissen, S.E., Pocock, S., Poulter, N.R., Ravn, L.S., et al. LEADER Steering Committee, LEADER Trial Investigators. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N. Engl. J. Med. 375 (2016), 311–322.
42. Mathew, H., Farr, O.M., Mantzoros, C.S., Metabolic health and weight: Understanding metabolically unhealthy normal weight or metabolically healthy obese patients. Metabolism 65 (2016), 73–80.
43. McLaughlin, T., Abbasi, F., Lamendola, C., Reaven, G., Heterogeneity in the prevalence of risk factors for cardiovascular disease and type 2 diabetes mellitus in obese individuals: effect of differences in insulin sensitivity. Arch. Intern. Med. 167 (2007), 642–648.
44. Meier, J.J., GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat. Rev. Endocrinol. 8 (2012), 728–742.
45. Meigs, J.B., Wilson, P.W., Fox, C.S., Vasan, R.S., Nathan, D.M., Sullivan, L.M., D'Agostino, R.B., Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease. J. Clin. Endocrinol. Metab. 91 (2006), 2906–2912.
46. Mørkedal, B., Vatten, L.J., Romundstad, P.R., Laugsand, L.E., Janszky, I., Risk of myocardial infarction and heart failure among metabolically healthy but obese individuals: HUNT (Nord-Trøndelag Health Study), Norway. J. Am. Coll. Cardiol. 63 (2014), 1071–1078.
47. Murphy, N., Cross, A.J., Abubakar, M., Jenab, M., Aleksandrova, K., Boutron-Ruault, M.C., Dossus, L., Racine, A., Kühn, T., Katzke, V.A., et al. A Nested Case-Control Study of Metabolically Defined Body Size Phenotypes and Risk of Colorectal Cancer in the European Prospective Investigation into Cancer and Nutrition (EPIC). PLoS Med., 13, 2016, e1001988.
48. NCD Risk Factor Collaboration (NCD-RisC). Trends in adult body-mass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19·2 million participants. Lancet 387 (2016), 1377–1396.
49. Nolan, C.J., Ruderman, N.B., Kahn, S.E., Pedersen, O., Prentki, M., Insulin resistance as a physiological defense against metabolic stress: implications for the management of subsets of type 2 diabetes. Diabetes 64 (2015), 673–686.
50. Nordestgaard, B.G., Palmer, T.M., Benn, M., Zacho, J., Tybjaerg-Hansen, A., Davey Smith, G., Timpson, N.J., The effect of elevated body mass index on ischemic heart disease risk: causal estimates from a Mendelian randomisation approach. PLoS Med., 9, 2012, e1001212.
51. O'Rahilly, S., Human genetics illuminates the paths to metabolic disease. Nature 462 (2009), 307–314.
52. Paruthi, J., Gill, N., Mantzoros, C.S., Adipokines in the HIV/HAART-associated lipodystrophy syndrome. Metabolism 62 (2013), 1199–1205.
53. Patni, N., Garg, A., Congenital generalized lipodystrophies–new insights into metabolic dysfunction. Nat. Rev. Endocrinol. 11 (2015), 522–534.
54. Pellegrinelli, V., Carobbio, S., Vidal-Puig, A., Adipose tissue plasticity: how fat depots respond differently to pathophysiological cues. Diabetologia 59 (2016), 1075–1088.
55. Phillips, C.M., Metabolically healthy obesity across the life course: epidemiology, determinants, and implications. Ann. N Y Acad. Sci. 1391 (2017), 85–100.
56. Pinnick, K.E., Neville, M.J., Fielding, B.A., Frayn, K.N., Karpe, F., Hodson, L., Gluteofemoral adipose tissue plays a major role in production of the lipokine palmitoleate in humans. Diabetes 61 (2012), 1399–1403.
57. Pou, K.M., Massaro, J.M., Hoffmann, U., Lieb, K., Vasan, R.S., O'Donnell, C.J., Fox, C.S., Patterns of abdominal fat distribution: the Framingham Heart Study. Diabetes Care 32 (2009), 481–485.
58. Robbins, A.L., Savage, D.B., The genetics of lipid storage and human lipodystrophies. Trends Mol. Med. 21 (2015), 433–438.
59. Rosen, E.D., Spiegelman, B.M., What we talk about when we talk about fat. Cell 156 (2014), 20–44.
60. Ross, R., Blair, S.N., Arena, R., Church, T.S., Després, J.P., Franklin, B.A., Haskell, W.L., Kaminsky, L.A., Levine, B.D., Lavie, C.J., et al. American Heart Association Physical Activity Committee of the Council on Lifestyle and Cardiometabolic Health Council on Clinical Cardiology Council on Epidemiology and Prevention Council on Cardiovascular and Stroke Nursing Council on Functional Genomics and Translational Biology, Stroke Council. Importance of Assessing Cardiorespiratory Fitness in Clinical Practice: A Case for Fitness as a Clinical Vital Sign: A Scientific Statement From the American Heart Association. Circulation 134 (2016), e653–e699.
61. Ruderman, N.B., Schneider, S.H., Berchtold, P., The “metabolically-obese,” normal-weight individual. Am. J. Clin. Nutr. 34 (1981), 1617–1621.
62. Ruderman, N., Chisholm, D., Pi-Sunyer, X., Schneider, S., The metabolically obese, normal-weight individual revisited. Diabetes 47 (1998), 699–713.
63. Sahakyan, K.R., Somers, V.K., Rodriguez-Escudero, J.P., Hodge, D.O., Carter, R.E., Sochor, O., Coutinho, T., Jensen, M.D., Roger, V.L., Singh, P., Lopez-Jimenez, F., Normal-Weight Central Obesity: Implications for Total and Cardiovascular Mortality. Ann. Intern. Med. 163 (2015), 827–835.
64. Saltiel, A.R., Kahn, C.R., Insulin signalling and the regulation of glucose and lipid metabolism. Nature 414 (2001), 799–806.
65. Samocha-Bonet, D., Dixit, V.D., Kahn, C.R., Leibel, R.L., Lin, X., Nieuwdorp, M., Pietiläinen, K.H., Rabasa-Lhoret, R., Roden, M., Scherer, P.E., et al. Metabolically healthy and unhealthy obese–the 2013 Stock Conference report. Obes. Rev. 15 (2014), 697–708.
66. Scott, R.A., Fall, T., Pasko, D., Barker, A., Sharp, S.J., Arriola, L., Balkau, B., Barricarte, A., Barroso, I., Boeing, H., et al. RISC Study Group, EPIC-InterAct Consortium. Common genetic variants highlight the role of insulin resistance and body fat distribution in type 2 diabetes, independent of obesity. Diabetes 63 (2014), 4378–4387.
67. Semple, R.K., Savage, D.B., Cochran, E.K., Gorden, P., O'Rahilly, S., Genetic syndromes of severe insulin resistance. Endocr. Rev. 32 (2011), 498–514.
68. Shimabukuro, M., Koyama, K., Lee, Y., Unger, R.H., Leptin- or troglitazone-induced lipopenia protects islets from interleukin 1beta cytotoxicity. J. Clin. Invest. 100 (1997), 1750–1754.
69. Shulman, G.I., Ectopic fat in insulin resistance, dyslipidemia, and cardiometabolic disease. N. Engl. J. Med. 371 (2014), 1131–1141.
70. Smith, U., Kahn, B.B., Adipose tissue regulates insulin sensitivity: role of adipogenesis, de novo lipogenesis and novel lipids. J. Intern. Med. 280 (2016), 465–475.
71. Stefan, N., Kantartzis, K., Machann, J., Schick, F., Thamer, C., Rittig, K., Balletshofer, B., Machicao, F., Fritsche, A., Häring, H.U., Identification and characterization of metabolically benign obesity in humans. Arch. Intern. Med. 168 (2008), 1609–1616.
72. Stefan, N., Kantartzis, K., Celebi, N., Staiger, H., Machann, J., Schick, F., Cegan, A., Elcnerova, M., Schleicher, E., Fritsche, A., Häring, H.U., Circulating palmitoleate strongly and independently predicts insulin sensitivity in humans. Diabetes Care 33 (2010), 405–407.
73. Stefan, N., Häring, H.U., Hu, F.B., Schulze, M.B., Metabolically healthy obesity: epidemiology, mechanisms, and clinical implications. Lancet Diabetes Endocrinol. 1 (2013), 152–162.
74. Stefan, N., Fritsche, A., Häring, H.U., Mechanisms explaining the relationship between metabolically healthy obesity and cardiovascular risk. J. Am. Coll. Cardiol. 63 (2014), 2748–2749.
75. Stefan, N., Fritsche, A., Schick, F., Häring, H.U., Phenotypes of prediabetes and stratification of cardiometabolic risk. Lancet Diabetes Endocrinol. 4 (2016), 789–798.
76. Stern, J.H., Rutkowski, J.M., Scherer, P.E., Adiponectin, Leptin, and Fatty Acids in the Maintenance of Metabolic Homeostasis through Adipose Tissue Crosstalk. Cell Metab. 23 (2016), 770–784.
77. Tan, C.Y., Vidal-Puig, A., Adipose tissue expandability: the metabolic problems of obesity may arise from the inability to become more obese. Biochem. Soc. Trans. 36 (2008), 935–940.
78. Tchkonia, T., Thomou, T., Zhu, Y., Karagiannides, I., Pothoulakis, C., Jensen, M.D., Kirkland, J.L., Mechanisms and metabolic implications of regional differences among fat depots. Cell Metab. 17 (2013), 644–656.
79. Wildman, R.P., Muntner, P., Reynolds, K., McGinn, A.P., Rajpathak, S., Wylie-Rosett, J., Sowers, M.R., The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999-2004). Arch. Intern. Med. 168 (2008), 1617–1624.
80. White, U.A., Fitch, M.D., Beyl, R.A., Hellerstein, M.K., Ravussin, E., Differences in In Vivo Cellular Kinetics in Abdominal and Femoral Subcutaneous Adipose Tissue in Women. Diabetes 65 (2016), 1642–1647.
81. Yaghootkar, H., Scott, R.A., White, C.C., Zhang, W., Speliotes, E., Munroe, P.B., Ehret, G.B., Bis, J.C., Fox, C.S., Walker, M., et al. Genetic evidence for a normal-weight “metabolically obese” phenotype linking insulin resistance, hypertension, coronary artery disease, and type 2 diabetes. Diabetes 63 (2014), 4369–4377.
82. Yaghootkar, H., Lotta, L.A., Tyrrell, J., Smit, R.A., Jones, S.E., Donnelly, L., Beaumont, R., Campbell, A., Tuke, M.A., Hayward, C., et al. Genetic Evidence for a Link Between Favorable Adiposity and Lower Risk of Type 2 Diabetes, Hypertension, and Heart Disease. Diabetes 65 (2016), 2448–2460.